Oncotelic Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1992
Net Income	-7.9	17.82	-11.39	-11.5	-7.39	Upgrade
Depreciation & Amortization	0	0.01	0.06	0.36	0.06	Upgrade
Share-Based Compensation	0	0.9	0.76	2.15	0.34	Upgrade
Other Operating Activities	6.58	-20.19	6.13	6.18	4.71	Upgrade
Operating Cash Flow	-1.32	-1.45	-4.43	-2.81	-2.28	Upgrade
Acquisitions	0	0	0	0	0.19	Upgrade
Investing Cash Flow	0	0	0	0	0.19	Upgrade
Common Stock Issued	0	0.16	1.97	2.93	0.08	Upgrade
Share Repurchases	-0.13	0	0	0	0	Upgrade
Other Financing Activities	1.13	0.97	2.56	0.3	2.09	Upgrade
Financing Cash Flow	1.25	1.13	4.53	3.22	2.17	Upgrade
Net Cash Flow	-0.07	-0.33	0.09	0.41	0.08	Upgrade
Free Cash Flow	-1.32	-1.45	-4.43	-2.81	-2.28	Upgrade
Free Cash Flow Margin	-1887.21%	-	-	-161.53%	-	Upgrade
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.03	-0.04	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.